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p53 plays a central role in prevention of normal cell from the development of the malignant phenotype. Somatic alterations (mutations, 
loss of heterozygosity, deletions) in p53 are a hallmark of most human cancers and cause defects in normal p53 function. However, 
in the tumors harboring wild-type p53, there are alterations in the regulation of the p53. Thus, understanding why p53 is unable 
to perform its role as a tumor suppressor in these wild-type tumors is very crucial. Germ-line polymorphisms in p53 are also an-
ticipated to cause measurable disturbance in p53 function. Over-expression as well as polymorphic variants of MDM2 might have 
effects on cancer development. In addition, degradation of p53 by E6 protein of high risk human papillomavirus is also suggested 
as one of the mechanisms which attenuate p53 responses in oral carcinogenesis. p53 has also been demonstrated to mediate cellular 
responses upon various DNA damaging cancer therapies, importantly, apoptosis. These responses have been implicated in an indi-
vidual’s ability to respond to these cancer therapies. Thus, exploring mechanisms by which normal function of p53 is affected in the 
comprehensive way in oral cancer might aid in the identification of tumor characteristics, prognosis and thus in the development 
of a new approach to treat the oral cancer.
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One third world burden of oral cancer cases is re-
ported from India [1]. Though, tobacco usage is an es-
tablished risk factor for oral cancer development, the 
role of high-risk human papillomavirus (HR-HPV) 
in etiopathogenesis of oral cancer has come up in most 
of the epidemiological studies [2, 3]. It has been re-
ported that the clinico-pathological and molecular 
pathological profile of tobacco-smoking and alcohol 
associated oral cancers in the western countries were 
different from tobacco-chewing associated oral can-
cers, mainly in the Indian subcontinent [4]. Further, 
human papillomavirus (HPV) positive oral cancer 
patients show different molecular properties and are 
considered as a distinct clinical-pathological entity 
with different outcomes and response to treatment 
as compared to HPV negative oral cancer patients [5]. 
Beside the above mentioned exogenous risk factors, 
inherited genetic factors also make an individual sus-
ceptible to oral cancer development.
Cancer develops through the accumulation 
of genetic alterations in genes involved in cell cycle 
regulation, angiogenesis, apoptosis, DNA repair, 
etc [6]. Oral cancer occurs as a consequence of vari-
ous molecular events that collectively develop from 
an exposure to carcinogens present in the environment 
and an individual’s genetic susceptibility [7]. This leads 
to damage of individual genes or portions of genetic 
materials. Most of these alterations involve activa-
tion of proto-oncogenes and/or inactivation of tumor 
suppressor genes. Many investigators have evaluated 
a range of molecular markers involved in the oral car-
cinogenesis, including molecules involved in the cell 
cycle regulation, DNA repair, apoptosis, angiogenesis 
and extracellular matrix degradation. However, the ex-
isting data about the role of molecular markers in oral 
cancer development are still unclear and inconclusive.
p53, a tumor suppressor gene has come up to the 
forefront of cancer research because it is commonly 
mutated in human cancer. Curiosity in the p53 has 
generated a large amount of information regarding 
the complexity of its function and regulation in carci-
nogenesis.
The p53 gene is located on the short arm of chro-
mosome 17 with 11 exons, of which 10 are coding. 
The p53 protein is comprised of 393 amino acids and 
divided into five domains with each domain having 
a different structure and function. The most important 
role of p53 is to integrate signals emerging from a wide 
range of cellular stresses, including stresses due to en-
vironmental carcinogen exposure. p53 induces adap-
tive and protective cellular responses through trigger-
ing the transcription of specific genes which prevent 
erroneous cell proliferation, by inducing growth arrest 
at the stage of cell cycle followed by DNA damage 
or apoptosis, if the damage is not repairable. Thus, 
it preserves the integrity of the genome (Fig. 1). These 
functions of p53 make this protein as the “guardian 
of the genome” [8].
Disturbance in the p53 is an almost frequent event 
in cancerous tumors. Somatic mutations in p53 with 
the aim of absence or dysfunction in p53 protein 
is one of the most universal mechanisms by which 
the p53 pathway is damaged during carcinogenesis. 
These mutations are mainly single base substitutions 
that result in amino acid substitution [9]. Importantly, 
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these missense mutations in p53 gene are usually 
followed by loss of heterozygosity (LOH), suggesting 
that there is a selective advantage conferred by losing 
the remaining wild-type p53, even after one allele has 
been mutated [10]. It was also reported that p53 LOH 
is a critical prerequisite for missense mutant p53 stabi-
lization and gain of function (GOF) in vivo [11]. Further, 
it was also observed that deletion at 17p13.1 locus 
of TP53 gene was among the most common altera-
tions found in primary solid tumors [12]. Unlike these 
somatic alterations, the majority of polymorphisms 
in the p53 gene are also expected to be associated 
with cancer risk by compromising the normal ac-
tivities of p53 [9]. The levels of p53 in normal cell are 
tightly controlled. Under normal conditions, mouse 
double minute 2 (MDM2), a key negative regulator 
of p53 binds to its transactivation domain and ubiquity-
lates, targeting it for degradation [13]. Since p53 tran-
scriptionally activates MDM2, the expression levels 
of p53 and MDM2 are balanced through a feedback 
negative loop. This balance is altered in stresses such 
as DNA damage which leads to increased p53 levels 
[14]. Underlying this crucial role of MDM2 in the con-
trol of p53 functions suggested that polymorphisms 
in the MDM2 gene may be responsible for probable 
alterations in p53 functions. Moreover, degradation 
of p53 by E6 protein of HR-HPV is also one of the 
mechanism by which normal function of p53 is altered 
in HPV associated oral carcinogenesis [3]. Together, 
all of above mentioned mechanisms leads to altera-
tions in p53 responses in cancer cell (Fig. 2). Thus, 
exploring mechanisms by which p53 responses are 
affected in the comprehensive way might aid in the 
identification of tumor characteristics, prognosis and 
thus in the development of a new approach to treat 
cancer. The present review aims to summarize ad-
vances in p53 research, especially in oral cancer with 
special emphasis on somatic mutations and germ-line 
polymorphisms in the p53 gene.
p53 MUTATIONS IN ORAL CANCER
Approximately, 10% (hematopoietic malignan-
cies) to 50–70% of all other human cancers are found 
to have somatic mutations in the p53 gene [15]. The 
frequency of p53 mutations also varies according 
to the tumor type [16]. Wide variations in the frequency 
of p53 mutations have been reported between differ-
ent studies of the same tumor type, probably reflecting 
methodological and geographic differences [17]. Also 
the frequency of p53 mutations has been also ob-
served to vary between groups which differ in ethnicity 
or nationality for some cancer types [18]. This may 
be due to specific carcinogen exposure or inherited 
features in those populations.
Cancer-associated mutations in p53 are primarily 
missense substitutions non-randomly distributed along 
the molecule, particularly in the central DNA binding 
domain [15]. These single amino acid changes affect 
Fig. 1. Tumor suppressor gene p53; guardian of the genome
Fig. 2. Mechanisms that lead to alteration in p53 responses
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transcriptional activity of p53 to various degrees. How-
ever, all mutations do not have an equal deleterious 
effect on p53 function, and some missense mutants 
may even acquire new functions [15, 19]. Different 
mutations have different effect on the function of the 
p53 protein. Evidences also have suggested that mutant 
p53 not only loses its tumor suppressive function, but 
also has dominant negative effect on the remaining wild-
type allele [20]. Moreover, mutant p53 has also ability 
to transcriptionally activate genes involved in increased 
proliferation, inhibition of apoptosis, limitless replica-
tion, angiogenesis, invasion and metastasis, etc [10, 
16]. Thus, mutant p53 promotes tumorigenesis through 
many different aspects of oncogenetic processes and 
hence, mutant p53 may play a central role in tumori-
genesis, almost in all the “hallmarks of cancer” (Fig. 3). 
However, how different forms of mutant p53 affect 
tumorigenesis is still unclear.
Fig. 3. Mutant p53 contributes to tumorigenesis
In head and neck tumors, the prevalence of p53 mu-
tation varies from 30% to 70%, depending on the 
metho dologies used to assess p53 mutations, types 
of the tumor material and heterogeneity of the tu-
mor sites examined [18]. The other reason for these 
wide variations could be different levels of exposure 
to risk factors like, tobacco and alcohol in the studied 
populations as mentioned earlier. There are reports 
on p53 mutation profile in oral cancers from various 
regions of India also. Reports from Southern India 
showed p53 mutations in 17% and 21% of oral cancer 
cases [21, 22]. Studies from Western and Northern 
region also reported that 17% of oral cancer patients 
harbor p53 mutations [23, 24]. In contrast, no p53 mu-
tations were reported in the study from Orissa, the 
Eastern region of India [25].
It was suggested that the incidence of p53 mutations 
in oral cancer patients was associated with a history 
of tobacco use [26, 27]. However, there are the studies 
which have reported no association of p53 mutation with 
smoking [28]. Further, it was observed that the p53 mu-
tation frequency in betel quid/tobacco-associated 
Asian oral cancer (15%) was significantly different from 
worldwide oral cancers, i.e. 46% [29]. There are reports 
which suggested that p53 mutation pattern also differ 
in group of having different type of tobacco habits [30, 
31]. Recently, we observed different type of base pair 
changes and the multiple mutations in p53 gene in oral 
cancer patients which suggest DNA insults by several 
different carcinogens which are present in smokeless 
tobacco. Our results on p53 mutation spectrum strongly 
support the notion that ethnic/geographic and dif-
ferences in tobacco consuming habits are the major 
cause of variations in the p53 mutations [32]. Thus, 
the p53 mutational pattern has been recommended 
to be a clinically appropriate “molecular sensor” for 
genotoxic exposure to carcinogens present in the en-
vironment and endogenous mutagens [33].
p53 POLYMORPHISMS IN ORAL CANCER
Several sequence variations are present in the 
p53 gene. Most of these variations are intronic and 
have no cancer related biological consequenc-
es [9]. The International Agency for Research 
on Cancer (IARC) TP53 mutation database lists 
29 common polymorphisms in the non-coding 
region of TP53 [34]. However, of which, two in-
tronic polymorphisms in p53 gene; 16 bp duplication 
in intron 3 (rs17878362) and G>A transition in intron 
6 (rs1625895) have been suggested to affect the 
levels of p53 gene expression as well as its func-
tions [35]. Also, it is important to mention that the 
functional role of these two intronic polymorphisms 
of p53 in cancer risk remains uncertain which is dis-
cussed in detail in our previous article [36]. Very few 
studies have reported the association between these 
two intronic polymorphisms and oral cancer risk. Galli 
et al. [37] have reported that intron 3 polymorphism 
was associated with increased oral cancer risk. 
However, the same study also suggested that intron 
6 polymorphism was associated with reduced oral 
cancer risk in Italian population. From India, only one 
study has analyzed the association between these 
two polymorphisms and oral cancer risk. The results 
revealed no association between intron 3 polymor-
phism and oral cancer risk; however, a variant allele 
at intron 6 was protective for oral cancer development 
in population from east region of India [38]. However, 
in our study, none of this intronic polymorphism was 
significantly associated with oral cancer risk in popu-
lation from West India [36].
Of the 19 exonic polymorphisms, 11 polymor-
phisms in p53 are non-synonymous, resulting 
in an amino-acid change and only four of these 
have been validated. Out of these, there are suf-
ficient molecular evidences for two polymorphisms 
(Pro47Ser and Arg72Pro) suggesting their role 
in functional change of the p53 protein. The rest two 
polymorphisms (V217M and G360A) have not been 
associated with an altered cancer risk till date [9]. The 
codon 47 polymorphism resulting in proline to ser-
ine substitution is rare whereas arginine to proline 
substitution in codon 72 is common [39, 40]. It was 
reported that Arg to Pro polymorphism at codon 
72 in exon 4 affects the structure of p53 protein and 
its biochemical and biological activities [41]. In our 
previous article, we have discussed various studies, 
which have reported how this polymorphism affects 
various important functions of p53 such as cell cycle 
regulation, apoptosis, transcriptional trans-activation 
capacity and senescence (Fig. 4) [36].
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Fig. 4. p53  Arg72Pro polymorphism and its influence 
on p53 functions
It was also observed that the p53 protein harbor-
ing Arg allele was more susceptible to degradation 
by HPV E6 protein and had a significantly higher fre-
quency of p53 mutations [42, 43]. Moreover, it was 
also reported that there is a tissue specific influence 
of Arg72Pro polymorphism on apoptosis [44]. Recent-
ly, Hu et al. [45] observed that Pro form of p53 gene has 
significantly higher levels of BPDE induced apoptotic 
index compared to Arg form in primary lymphocytes. 
Moreover, the Arg form of p53 gene was associated 
with poor apoptosis in head and neck tumors [46]. 
Such tissue specific function of this polymorphism 
may explain why most of the epidemiological studies 
remain inconclusive.
We have discussed various studies from India in our 
previous research article and observed that no signifi-
cant association of Arg72Pro polymorphism with oral 
cancer risk was observed in most of studies [36]. Fur-
ther, it was suggested that the association of Arg72Pro 
polymorphism with cancer risk was modulated by eth-
nicity, allelic frequency, histological and anatomical 
sites of tumors [47]. However, recent meta-analysis 
of Arg72Pro polymorphism of p53 suggests no as-
sociation of this polymorphism with oral cancer risk 
as even after stratifying by ethnicity [48]. Also, a recent 
meta-analysis by Mandal et al. [49] suggested that 
Arg72Pro polymorphism may not be an independent 
risk factor for cancer in Indian population. However, 
still to provide conclusive results, all the intronic and 
exonic polymorphisms should be considered simulta-
neously. Our recent study considering all these three 
polymorphisms simultaneously suggested that carri-
ers of absence of 16 bp duplication allele at intron 3, 
proline allele at exon 4 and G allele at intron 6 were 
protected from oral cancer development [36].
p53 can also be inactivated by alternative mecha-
nisms other than somatic mutations and germ-line 
polymorphisms. Here we summarize two important 
events that alternatively inactivate p53: (1) Polymor-
phisms in MDM2 gene and (2) HPV infections.
MDM2 AND ITS ASSOCIATION WITH p53
Because MDM2 is a key negative regulator 
of p53 activity, over-expression of MDM2 inhibits the 
p53 responses. Hence, in order to activate p53, euka-
ryotic cells have to develop mechanisms to block this 
negative feedback regulation in response to variety 
of stress. These mechanisms include posttranslational 
modification of either p53 or MDM2 such as acetyla-
tion, phosphorylation and protein-protein interaction. 
However, cancers often take advantages of this feed-
back loop to promote their growth as various tumors 
express high levels of MDM2 through distinct mecha-
nisms without p53 mutations [50]. It has been reported 
that MDM2 transgenic mice expressing higher levels 
of MDM2 in various tissues, develop spontaneous 
tumors compared to non-transgenic mice [13]. Thus, 
over-expression of MDM2 has an effect on tumor 
susceptibility in mice. In fact, reports suggest that 
over-expression of MDM2 commonly occurs in oral 
cancer [51, 52]. Recently, novel MDM2 splice variants 
were identified in oral cancer at a high frequency and 
were found to be significantly associated with oral 
cancer development [53]. Taken together, MDM2 may 
play a significant role in oral carcinogenesis. Therefore, 
it is biologically plausible that functional genetic vari-
ants in the MDM2 gene may have an effect on cancer 
development in the general population.
It has been reported that one intronic polymor-
phism (T>G in the Sp1-binding site within the intronic 
promoter region, rs2279744) of MDM2 may increase 
the affinity of the Sp1 transcriptional factor, which re-
sults in higher MDM2 mRNA and protein levels. Thus, 
the presence of this polymorphism may attenuate 
the p53 responses, hence increasing cancer sus-
ceptibility [9, 54]. There are very few studies, which 
have investigated the association of this MDM2 poly-
morphism with oral cancer risk. Two risk association 
studies highlighted that MDM2 polymorphism did not 
alter the risk of oral cancer, but may influence the age 
of disease onset [13, 55]. A study on MDM2 polymor-
phism and oral cancer risk from India suggested that 
this polymorphism could not modify the risk of oral 
cancer independently [56]. However, authors sug-
gested that this polymorphism may modulate cancer 
risk in combination with p53 and p73 polymorphisms. 
More interestingly, a recent meta-analysis by Zhuo 
et al. [57] also suggested that homozygote GG alleles 
of MDM2 SNP309 may be a low-penetrant risk factor 
for HNC, and G allele may confer nasopharyngeal 
cancer susceptibility.
HPV INFECTION AND ITS ASSOCIATION 
WITH p53 PROTEIN
The participation of HPV in oral carcinogenesis 
was first proposed by Syrjanen et al. in 1983 [58]. 
HPVs have been divided into two groups: (1) High 
Risk HPV (HR-HPV) and (2) Low Risk (LR-HPV). HR-
HPVs are mainly associated with potentially malignant 
lesions, e.g. HPV 16 and 18, whereas LR-HPVs are 
more commonly associated with benign diseases, e.g. 
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HPV 6 and 11 [3]. The molecular mechanisms by which 
HPVs disrupt key cellular elements responsible for cell 
cycle regulation and apoptosis have been identified. 
HPV E6 oncoprotein degrades p53 protein. Thus, cells 
that contain damaged DNA enter aberrantly into mito-
sis, sustain proliferative ability and may eventually con-
tribute to the propagation of structural chromosomal 
abnormalities in HR-HPV associated cancer [59].
Various investigators have reported prevalence 
of HPV infection in oral cancer worldwide [60–63]. 
However, results show large variations from low preva-
lence to high prevalence. Also several reports from 
Bangladesh, various countries from central Europe 
and Latin America did not find HPV infection in oral 
cancer [64–67]. There are large regional and time 
trend variations in prevalence rates of HPV in oral 
cancers [68]. Recent reviews suggest that separa-
tion of oral carcinoma from the heterogeneous group 
of head and neck carcinomas is very essential to gain 
valid results of HPV prevalence in oral cancers [60, 62].
Prevalence of HR-HPV type 16 and 18 infections 
in oral cancers varies widely across the different geo-
graphical regions of India. Prevalence of HPV 16 infec-
tion is reported to vary from 6% to 45.8%, whereas HPV 
18 infection from 0% to 54.2% of oral cancers from 
India which was reviewed in our previous article [69]. 
HPV positive oral cancers are highest from Southern 
India, while the Western part of the country (Mumbai) 
exhibits low HPV positive oral cancers [69]. Recently, 
we have reported absence of HPV16 and 18 infections 
in oral cancer patients in population from Gujarat, West 
India [69].
p53 ALTERATIONS 
AND CLINICOPATHOLOGICAL 
CHARACTERISTICS
The prognostic value of p53 in oral cancer has 
long been debated. Contradictory results have been 
published about the presence or absence of p53 gene 
mutations and the outcome in oral cancer. Yamazaki 
et al. [70] suggested that mutations within the DNA 
binding domain of p53 could be important prognostic 
factors for locoregional failure, lymph node metastasis 
and the occurrence of subsequent distant metastasis 
in oral cancers. It was also reported that a dominant 
negative mutation in p53 may be a good predictor 
of early recurrence in oral cancer patients [71]. How-
ever, Tsurusako et al. [72] suggested that p53 muta-
tions may not be strongly involved in the development 
of well differentiated tongue cancers. In a recent study, 
faster tumor growth, higher frequency of metastasis 
in cervical lymph node and shorter survival was ob-
served in mice injected with cells harboring disruptive 
p53 mutations as compared to mice injected with cells 
lacking these mutations [73]. Also the results of our 
study strongly suggest that evaluation of p53 muta-
tion status could be useful for predicting loco-regional 
recurrence at early stage among oral cancer patients. 
Further, detection of p53 mutation in apparently nor-
mal adjacent mucosa along with mutation with tumor 
tissues should be done for prognostication. p53 muta-
tions also affect the survival rate as cases with truncat-
ing and transcriptionally non-active p53 mutations had 
poor disease free as well as overall survival [32]. How-
ever, the results of a recent meta-analysis by Tandon 
et al. [74] highlights that the existing data regarding the 
prognostic importance of p53 are indecisive and there 
is a great heterogeneity observed in various studies.
It was also observed that MDM2 GG genotype and 
p53 mutations were associated with poor disease-
free survival in both early and lymph node positive 
advanced stage oral cancer patients [75]. In a multi-
centeric study by the IARC, an inverse association was 
observed between the incidence of p53 mutations and 
HPV 16 positivity in oral cancer patients [76]. However, 
Kozomara et al. [77] suggested that p53 mutations 
in combination with HPV infections were associated 
with an increased risk of recurrence and worse progno-
sis in oral cancer patients. The HPV positive oral cancer 
had improved outcome [5, 63, 78]. Further, it was 
suggested that inactivation of p53 protein by HPV 
is not as harmful as the mutations induced by other 
carcinogens present in environment [2]. It may be be-
cause the wild type p53, which escape HPV mediated 
degradation, might trigger cellular apoptosis following 
cancer therapy.
ASSOCIATION OF p53 ALTERATIONS 
WITH TREATMENT OUTCOME
The most used line of treatment for oral cancers 
is surgery followed by radiotherapy and/or chemo-
therapy. Multitasking of p53 is essential for the sup-
pression of tumor, as well as for activating the cellular 
responses to DNA damage inducing cancer therapies 
such as radiotherapy and chemotherapy [79]. It was 
reported that p53 mutations in the DNA binding do-
main might be useful to predict the radioresistance 
in oral cancer patients [80]. Yasumoto et al. [81] sug-
gested that the X-ray sensitivity of wild type p53 cells 
may come from the expression of genes involved 
in apoptosis. Moreover, Tu et al. [82] suggested that 
both MDM2 T>G and p53 Arg72Pro polymorphisms 
could be useful for evaluating the outcome of ad-
vanced oral cancers treated with adjuvant radiation.
Interest in cisplatin-based neoadjuvant chemo-
therapy has recently emerged due to its survival 
benefits in patients with locally advanced oral can-
cer. Recently, Perrone et al. [83] suggested that 
the mutant p53 proteins with loss of function may 
predict a significant low pathologic complete re-
mission rate and suboptimal response to cisplatin-
based neoadjuvant chemotherapy in patients with 
oral cancer. Moreover, sensitivity to cisplatin was 
positively associated with the presence of functional 
p53 in 60 human tumor cell lines of a National Cancer 
Institute (NCI) panel [84]. In addition, tumor cell lines 
that harbor non-functional p53 were more resistant 
to cisplatin than those harboring functional p53, but 
can be sensitized when reconstituted with wild-type 
p53 [85]. However, the association of p53 status and 
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cisplatin cytotoxicity depends on several other fac-
tors, like types of tumor cells, the presence of other 
genetic alterations etc. Further studies on such 
genetic alterations are required to determine the 
role of p53 in cisplatin cytotoxicity. Proteins that are 
involved in p53 pathways can also modulate p53 re-
sponses as mentioned above and thus, cisplatin 
cytotoxicity. It was suggested that MDM2 overex-
pression affects the p53 responses under stress 
conditions, even in the presence of wild type p53 and 
results in to faster cancer progression and resis-
tance to therapy in some tumor types [53]. Further, 
emerging evidence in the literature recommend that 
p53 (Arg72Pro) and MDM2 (T>G) and p53 protein 
degradation by HR-HPV as mentioned earlier could 
also determine the patients’ ability to induce p53 re-
sponses to DNA damaging therapies [79].
Various studies have confirmed that Arg72Pro 
polymorphism can affect the levels of apoptosis both 
in the context of wild type p53 and mutant p53. Wild 
type p53 in combination with Arg allele mediates the 
p53 dependent apoptotic response more efficiently. 
Interestingly, with mutant p53 protein, Pro allele 
could be associated with higher levels of apoptosis 
(Fig. 5) [79]. Also this observation was supported 
by two studies on advanced head and neck squamous 
cell carcinomas that received cisplatin based chemo-
radiotherapy. The authors observed that patients 
harboring wild type p53 and Arg genotype as well 
as patients with mutant p53 in combination with Pro 
genotypes had better response rates as well as overall 
and progression-free survival [79]. Further studies are 
recommended to understand these differences in the 
apoptotic response of p53 [86].
Fig. 5. p53 Arg72Pro polymorphism and mutation in combination 
affect its apoptotic function
Hence, knowledge of p53 somatic mutational sta-
tus as well as the p53 Arg72Pro genotype of the patient 
could help to delineate the patient populations that 
will respond to chemo-radiotherapies. However, the 
utility of p53 Arg72Pro polymorphism as a predictive 
biomarker requires mutational analysis of p53. A re-
cent study suggests that MDM2 T>G polymorphism 
is an independent predictive biomarker for selection 
of patients who respond to radical chemo-radiothe-
rapy [87]. Together, these studies of p53 Arg72Pro 
and MDM2 T>G indicated that high frequency 
SNPs in p53 pathway genes could affect the activity 
of p53 in cancer cells and thereby influences thera-
peutic responses.
In addition to this, p53-MDM2 pathway presents 
many molecular targets for screening small molecules 
as potential therapies for tumors harbouring wild type 
p53. A number of new small molecules have been 
identified to target MDM2 in the past decades and 
have entered Phase I clinical trials [50]. One of these 
compounds, Nutlin-3, binds with MDM2, dislodges 
p53 from MDM2 inducing p53-mediated apoptosis 
in leukemias, and is under phase I clinical trial for 
leukemia and solid tumors [88]. Further, a small 
molecule named JNJ-26854165 was shown to bind 
the RING domain of MDM2 and prevent the interac-
tion of the MDM2-p53 complex with the proteasome. 
This molecule has been put on phase I clinical trial 
for advanced solid tumors [88, 89]. Various others 
small molecule inhibitors of E3 ubiquitin ligase activity 
of MDM2 as well as the MDM2-p53 interaction have 
been revealed later and are currently under pre-clinical 
development [50]. More interestingly, some of natu-
rally derived molecules have been shown to decrease 
MDM2 expression and activity in vitro and in vivo, 
hence, inhibit the p53-MDM2 interaction [90]. In ad-
dition to the direct inhibitors, indirectly interrupting the 
MDM2-p53 negative feedback loop, which prevents 
MDM2-mediated degradation of p53, are also been 
explored for the development of molecule-targeted 
therapy for cancers [50]. Moreover, several miRNA 
have been identified that suppress MDM2, hence, 
miRNAs have become a new but important component 
of the p53 signaling pathway through regulating the 
p53/MDM2 feedback loop [91].
CONCLUSION
In nutshell, it can be suggested that incorporating 
information of the inherited genetic polymorphisms 
of the p53 pathway along with the somatic muta-
tions in p53, patient populations can be stratified and 
therapies could be better targeted. These data support 
a hypothesis that individuals could develop cancer 
that retains wild type p53, but still have an attenu-
ated p53 response because they may harbor genetic 
polymorphisms either in p53 gene or in MDM2 gene 
or HPV infection. Thus, comprehensive analysis of all 
the mechanisms by which p53 response is attenu-
ated in oral cancer, is very essential to improve our 
understanding of oral cancer pathogenesis. Further, 
this knowledge will aid in improving prognosis and 
treatment of oral cancer.
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